Trader’s Watch List: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Amyris, Inc. (NASDAQ:AMRS), Sonus Networks, Inc. (NASDAQ:SONS), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) belongs to Healthcare sector. Its weekly performance is 0.72%. On last trading day company shares ended up $8.42. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) distance from 50-day simple moving average (SMA50) is -5.72%. On 27 May, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science Inc. (kse:011000), an international DNA vaccine developer and manufacturer in which Inovio holds an equity interest.

Amyris, Inc. (NASDAQ:AMRS) shares moved up 5.53% in last trading session and ended the day at $2.10. AMRS Gross Margin is 25.50% and its return on assets is -27.90%. Amyris, Inc. (NASDAQ:AMRS) quarterly performance is -14.29%. Amyris, Inc. (NASDAQ:AMRS), announced that it participated in a panel discussion entitled, “Closer Examination of Next-Generation Bioproduct Technologies,” at Cowen and Company’s 43rd Annual Technology, Media & Telecom Conference. The conference held May 27-28, 2015, at The New York Palace Hotel in New York City.

On 02 June, Sonus Networks, Inc. (NASDAQ:SONS) shares moved down -0.26% and was closed at $7.77. SONS EPS growth in last 5 year was -30.50%. Sonus Networks, Inc. (NASDAQ:SONS) year to date (YTD) performance is -60.86%. The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action has been filed against Sonus Networks, Inc. (NASDAQ: SONS) on behalf of purchasers of the Company’s common stock between October 23, 2014 and March 24, 2015, inclusive (the “Class Period”).

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) ended the last trading day at $2.89. Company weekly volatility is calculated as 4.54% and price to cash ratio as 1.23. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) showed a weekly performance of -1.03%. Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) breached their fiduciary duties to shareholders. Eleven Biotherapeutics is a clinical-stage biopharmaceutical company that engages in the discovery and development of protein therapeutics to treat eye diseases, primarily in the United States.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved up 1.45% in last trading session and ended the day at $4.19. ARNA Gross Margin is 76.40% and its return on assets is -18.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is 3.71%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that the company presented a corporate overview and update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015, at the Grand Hyatt in New York, New York.

Leave a Reply

Your email address will not be published. Required fields are marked *